πŸ‡ΊπŸ‡Έ FDA

Intelligence Β· Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors β€” phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β€” searchable for business development and competitive intelligence.

91 results for β€œstandard” Clear

  1. AVELUMAB, DOSTARLIMAB, ATEZOLIZUMAB, AVELUMAB, CEMIPLIMAB, DOSTARLIMAB, NIVOLUMAB, PEMBROLIZUMAB, NIVOLUMAB, DURVALUMAB, CEMIPLIMAB, ATEZOLIZUMAB, PEMBROLIZUMAB, DURVALUMAB

    Ningbo Cancer Hospital

    Only patients with oncologic locally advanced or metastatic tumour (lung cancer, renal cell cancer (except IMDC favorable-risk treated Tyrosine Kinase Inhibitor [TKI] / immunotherapy [IO] combination), head and neck cancer, urothelial carcinoma, triple negative breast cancer, Merkel cancer, melanoma, hepatocellular carcinoma, colorectal carcinoma with microsatellite instability [MSI], esophageal squamous cell carcinoma, endometrial carcinoma, or cervical cancer, gastric/gastro-esophageal junction/esophageal adenocarcinoma, basal cell carcinoma or squamous skin carcinoma) in partial or complete response (except for melanoma, only patients in partial response) after 6 months of standard IO treatment (monotherapy or previously in combination with other immunotherapy (ipilimumab) or chemotherapy or continuous combination with pemetrexed or bevacizumab or TKI).

    phase 3 small molecule active

    1 trial

  2. CHLORURE DE SODIUM FRESENIUS 0,9 %, solution injectable, Tislelizumab

    The George Institute

    patients with a positive status for molecular residual disease (MRD) [MRD (+)] 2 to 5 months after the end of standard end of standard curative treatment

    phase 3 small molecule active

    1 trial

  3. Candesartan and standard chronic heart disease therapy

    Takeda

    Heart Failure

    phase 3 small molecule terminated

    1 trial

  4. Dapagliflozin+Standard Treatment for 12 weeks,washout period for 4 weeks，then Standard Treatment alone for12 weeks

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Pediatric Hereditary Kidney Diseases

    phase 3 small molecule active

    1 trial

  5. Direct-Acting Oral Anticoagulants (used as per local standard practice)

    United Therapeutics Europe Ltd

    Traumatic Intracranial Haemorrhage

    phase 3 small molecule active

    1 trial

  6. Drug Isotretinoin (13 cis retinoic acid ) capsules+standard treatment

    United Therapeutics Europe Ltd

    COVID19

    phase 3 small molecule active

    1 trial

  7. Enhanced standard management

    United Therapeutics Europe Ltd

    Pacemaker Complication

    phase 3 other active

    1 trial

  8. KEYTRUDA 25 mg/mL concentrate for solution for infusion, ALIMTA 500 mg powder for concentrate for solution for infusion

    Disc Medicine

    Patients with advanced, metastatic NSCLC that have not progressed on a standard of care immunotherapy regimen 6 months after initiation of first line treatment.

    phase 3 small molecule active

    1 trial

  9. Ozempic 1 mg solution for injection in pre-filled pen, Semaglutide placebo, solution for injection in 1.5 mL pre-filled PDS290 pen injector

    NovoThirteen

    While it is well-established that long-term good glycaemic control will reduce the risk of diabetic retinopathy development and progression, intensification of glycaemic control has also been associated with an initial worsening of diabetic retinopathy. This phenomenon is known as β€œearly worsening”. The rationale of this trial is to establish the long-term effects of semaglutide on diabetic retinopathy in subjects with type 2 diabetes (T2D) using validated and standardised ophthalmic assessments. This trial is a post-authorisation safety study (PASS) conducted as a commitment to the European Medicines Agency

    phase 3 small molecule active

    1 trial

  10. PEGASPARGASE

    Pari Pharma GmbH

    This is a prospective, French, multicenter, open-label, design, stratified on the immunophenotypic characterization (B- or T- lineage) and the patient risk group, that aims at evaluating the efficacy and the tolerance of different schedules of pegaspargase in patients from 12 months to less than 18 years newly diagnosed with standard/medium-risk ALL

    phase 3 small molecule active

    1 trial

  11. Placebo for Mepolizumab Injection, MEPOLIZUMAB, Placebo for Depemokimab Injection

    GlaxoSmithKline

    Relapsing or refractory Eosinophilic Granulomatosis with Polyangiitis (EGPA) receiving standard of care (SoC) therapy

    phase 3 small molecule active

    1 trial

  12. RITUXIMAB, METHOTREXATE, MYCOPHENOLATE MOFETIL, RoActemra 162 mg solution for injection in pre-filled pen., AZATHIOPRINE, XELJANZ 5 mg film-coated tablets

    Pari Pharma GmbH

    Patients with GPA and inadequate response to standard of care therapy defined as an inadequate response to either a combination of glucocorticoids plus cyclophosphamide AND/OR a combination of glucocorticoids plus rituximab.

    phase 3 small molecule active

    1 trial

  13. Standard Brief Intervention

    BRIGHT MINDS BIOSCIENCES INC.

    Drug Usage

    phase 3 other completed

    1 trial

  14. Standard Care

    BRIGHT MINDS BIOSCIENCES INC.

    HIV Infections

    phase 3 other completed

    1 trial

  15. Standard Care Intervention (SCI)

    BRIGHT MINDS BIOSCIENCES INC.

    Tobacco Dependence

    phase 3 other completed

    1 trial

  16. Standard First-Line Therapy

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Unresectable Colorectal Cancer

    phase 3 small molecule active

    1 trial

  17. Standard of Care

    Telix Innovations

    Metastatic Prostate Cancer

    phase 3 small molecule terminated

    1 trial

  18. Standard of Care

    AbbVie

    Non-Squamous Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  19. Standard of Care PO (oral) antibiotics

    United Therapeutics Europe Ltd

    Infections

    phase 3 small molecule active

    1 trial

  20. Standard of Care Treatment

    Kyverna Therapeutics

    Myasthenia Gravis

    phase 3 small molecule active

    1 trial

  21. Standard treatment: Control arm

    United Therapeutics Europe Ltd

    Cervical Carcinoma

    phase 3 other active

    1 trial

  22. The placebo product is manufactured to visually match the corresponding FDY-5301 injection drug product. It is formulated to match a standard saline solution comprised of Sodium Chloride and Water for Injection.

    Lacuna Pharma Pty Ltd

    Anterior ST-Elevation Myocardial Infarction

    phase 3 small molecule active

    1 trial

  23. -, -, CIMETIDINE , ROXATIDINE , FAMOTIDINE, COMBINATIONS, PARACETAMOL , RANITIDINE , NIZATIDINE , SKB264, FAMOTIDINE , -

    Lacuna Pharma Pty Ltd

    Metastatic or locally advanced unresectable solid tumors progressing after available standard therapies

    phase 2 small molecule active

    1 trial

  24. 514G3 (2 mg/kg) plus standard IV antibiotic treatment

    XBiotech Germany GmbH

    Staphylococcus Aureus Bacteremia

    phase 2 mab completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β€” verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources